QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies

In conclusion, we found a low risk of QTcF interval prolongation in children with RR-TB who received at least one QT-prolonging drug. Greater increases in maximum QTcF and ΔQTcF were observed when MFX and CFZ were used together. Future studies characterizing exposure-QTcF responses in children will be helpful to ensure safety with higher doses if required for effective treatment of RR-TB.PMID:37358463 | DOI:10.1128/aac.01448-22

Source: Antimicrobial Agents and Chemotherapy - June 26, 2023 Category: Microbiology Authors: Ali Mohamed Ali Kendra K Radtke Anneke C Hesseling Jana Winckler H Simon Schaaf Heather R Draper Bel én P Solans Louvina van der Laan Jennifer Hughes Barend Fourie James Nielsen Anthony J Garcia-Prats Rada M Savic Source Type: research